Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase
III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution
0.6% in children with a documented history of seasonal allergic conjunctivitis (SAC) or
perennial allergic conjunctivitis (PAC).